Whether you have questions about our treatment programmes, want to understand your funding options, or are ready to arrange an assessment, we are here to help
Affected individuals carry the virus in their bodies for the rest of their lives
Here's the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations
Recalls & Warnings October 05, 2019 Advocare to Pay $150 Million to Settle Charges of Operating a Pyramid Scheme AdvoCare International, the marketing company that sells Spark energy drink, as well as other nutrition products and supplements, has agreed to settle FTC charges that it operated an illegal pyramid scheme
Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH